Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average of $5.44

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $5.44 and traded as high as $6.03. Capricor Therapeutics shares last traded at $5.93, with a volume of 276,550 shares traded.

Wall Street Analyst Weigh In

Several research analysts have issued reports on CAPR shares. Cantor Fitzgerald started coverage on shares of Capricor Therapeutics in a research report on Friday, January 5th. They set an “overweight” rating and a $8.00 price objective on the stock. StockNews.com raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Friday, March 1st.

Capricor Therapeutics Stock Down 9.0 %

The firm has a market cap of $159.08 million, a PE ratio of -5.80 and a beta of 3.99. The company’s fifty day moving average price is $5.50 and its two-hundred day moving average price is $4.28.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.21. The business had revenue of $12.09 million for the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. As a group, analysts predict that Capricor Therapeutics Inc will post -0.83 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. BlackRock Inc. boosted its holdings in shares of Capricor Therapeutics by 46.3% in the third quarter. BlackRock Inc. now owns 437,228 shares of the biotechnology company’s stock valued at $2,623,000 after acquiring an additional 138,347 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Capricor Therapeutics by 28.8% in the second quarter. Geode Capital Management LLC now owns 298,322 shares of the biotechnology company’s stock valued at $1,426,000 after acquiring an additional 66,633 shares in the last quarter. Citigroup Inc. purchased a new stake in Capricor Therapeutics during the third quarter worth about $211,000. Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 5.6% during the first quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company’s stock worth $3,502,000 after buying an additional 54,260 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in Capricor Therapeutics during the fourth quarter worth about $258,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.